Skip to Content

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCGI1250


A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)

Principal Investigator(s)

Jordan Berlin


  • Protocol No. VICCGI1250
  • Open Date: 04/09/2013
  • Staging: Phase I/II
  • Age Group: Adults
  • Scope: National
  • Objective: Phase I: Determine the maximum tolerated dose (MTD) of temozolomide and pazopanib combination in patients with advanced PNET. Phase II: Determine the ORR.
  • Disease Sites: Pancreatic; Neuroendocrine
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Pazopanib; TMZ; Temodar; Temozolomide (TMZ)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01465659
  • Secondary Protocol No: NU 11I03


None Provided.


Not provided. Please call for more information.